The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation

Cancer Research

Volumn 68, Issue 12, 2008, Pages 4701-4708

  Meijer, Joost ^a   Ogink, Janneke ^a   Kreike, Bas ^a   Nuyten, Dimitry ^a   De Visser, Karin E ^a   Roos, Ed ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR6; CXCL16 CHEMOKINE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; PERTUSSIS TOXIN; ALPHA CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR; CXCL16 PROTEIN, HUMAN; CXCL16 PROTEIN, MOUSE; CXCR6 PROTEIN, HUMAN; CXCR6 PROTEIN, MOUSE; G PROTEIN COUPLED RECEPTOR; GRANULOCYTE CHEMOTACTIC PROTEIN 2; SCAVENGER RECEPTOR; VIRUS RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CARCINOGENESIS; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL CULTURE; COLON TUMOR; CYTOLOGY; DNA MICROARRAY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETICS; LUMINESCENCE; METABOLISM; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; TUMOR RECURRENCE; UDDER;

ANIMALS; BREAST NEOPLASMS; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CXCL6; CHEMOKINES, CXC; COLONIC NEOPLASMS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; LUMINESCENT MEASUREMENTS; MAMMARY GLANDS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; PERTUSSIS TOXIN; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, SCAVENGER; RECEPTORS, VIRUS;

EID: 49649117314     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0482     Document Type: Article

References (47)

1. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540-50.
2. Kulbe H, Levinson NR, Balkwill F, Wilson JL. The chemokine network in cancer - much more than directing cell movement. Int J Dev Biol 2004;48:489-96.
3. Zlotnik A. Chemokines and cancer. Int J Cancer 2006;119:2026-9.
4. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
5. Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003;63:3833-9.
6. Schimanski C, Schwald S, Simiantonaki N, et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 2005;11:1743-50.
7. Kim J, Takeuchi H, Lam S, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005;23:2744-53.
8. Katayama A, Ogino T, Bandoh N, Nonaka S, Harabuchi Y. Expression of CXCR4 and its down-regulation by IFN-γ in head and neck squamous cell carcinoma. Clin Cancer Res 2005;11:2937-46.
9. Kaifi J, Yekebas E, Schurr P, et al. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 2005;97:1840-7.
10. Scala S, Ottaiano A, Ascierto P, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005;11:1835-41.
11. Rubin J, Kung A, Klein R, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 2003;100:13513-8.
12. Meijer J, Zeelenberg IS, Sipos B, Roos E. The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. Cancer Res 2006;66:9576-82.
13. Burns J, Summers B, Wang Y, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006;203:2201-13.
14. Liao F, Alkhatib G, Peden K, Sharma G, Berger E, Farber J. STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J Exp Med 1997;185:2015-23.
15. Nanki T, Shimaoka T, Hayashida K, Taniguchi K, Yonehara S, Miyasaka N. Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis Rheum 2005;52:3004-14.
16. van der Voort R, van Lieshout AW, Toonen LW, et al. Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis Rheum 2005;52:1381-91.
17. Heydtmann M, Lalor P, Eksteen JA, Hubscher S, Briskin M, Adams D. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol 2005;174:1055-62.
18. + NKT cells patrolling liver sinusoids. PLoS Biol 2005;3:e113.
19. Patel D, Bailey S, Gresham J, et al. TLR4-NOX4-AP-1 signaling mediates lipopolysaccharide-induced CXCR6 expression in human aortic smooth muscle cells. Biochem Biophys Res Commun 2006;347:1113-20.
20. Matloubian M, David A, Engel S, Ryan J, Cyster J. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 2000;1:298-304.
21. Wilbanks A, Zondlo S, Murphy K, et al. Expression cloning of the STRL33/BONZO/TYMSTR ligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol 2001;166:5145-54.
22. Shimaoka T, Nakayama T, Kume N, et al. Cutting edge: SR-PSOX/CXC chemokine ligand 16 mediates bacterial phagocytosis by APCs through its chemokine domain. J Immunol 2003;171:1647-51.
23. Hase K, Murakami T, Takatsu H, et al. The membrane-bound chemokine CXCL16 expressed on follicle-associated epithelium and M cells mediates lympho-epithelial interaction in GALT. J Immunol 2006;176:43-51.
24. Gough P, Garton K, Wille P, Rychlewski M, Dempsey P, Raines E. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol 2004;172:3678-85.
25. Ludwig A, Weber C. Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb Haemost 2007;97:694-703.
26. Zeelenberg IS, Ruuls-Van Stalle L, Roos E. Retention of CXCR4 in the endoplasmic reticulum blocks dissemination of a T cell hybridoma. J Clin Invest 2001;108:269-77.
27. Silva J, Li M, Chang K, et al. Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 2005;37:1281-8.
28. Chen JD, Bai X, Yang AG, Cong Y, Chen SY. Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy. Nat Med 1997;3:1110-6.
29. Kimura A, Ohmichi M, Kurachi H, et al. Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line. Cancer Res 1999;59:5133-42.
30. Alderton F, Humphrey P, Sellers L. High-intensity p38 kinase activity is critical for p21cip1 induction and the antiproliferative function of Gi protein-coupled receptors. Mol Pharmacol 2001;59:1119-28.
31. Burdon D, Patel R, Challiss RA, Blank JL. Growth inhibition by the muscarinic M(3) acetylcholine receptor: evidence for p21(Cip1/Waf1) involvement in G(1) arrest. Biochem J 2002;367:549-59.
32. Krudewig R, Langer B, Vogler O, et al. Distinct internalization of M2 muscarinic acetylcholine receptors confers selective and long-lasting desensitization of signaling to phospholipase C. J Neurochem 2000;74:1721-30.
33. Tulipano G, Stumm R, Pfeiffer M, Kreienkamp H, Hollt V, Schulz S. Differential β-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem 2004;279:21374-82.
34. Nakajima M, Hutchinson HG, Fujinaga M, et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A 1995;92:10663-7.
35. Hein L, Meinel L, Pratt R, Dzau V, Kobilka B. Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol 1997;11:1266-77.
36. McArdle CA, Franklin J, Green L, Hislop JN. Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors. J Endocrinol 2002;173:1-11.
37. Sorkin A, McClure M, Huang F, Carter R. Interaction of EGF receptor and Grb2 in living cells visualized by fluorescence resonance energy transfer (FRET) microscopy. Curr Biol 2000;10:1395-8.
38. Pierce KL, Luttrell LM, Lefkowitz RJ. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 2001;20:1532-9.
39. Ou DL, Chen CL, Lin SB, Hsu CH, Lin LI. Chemokine receptor expression profiles in nasopharyngeal carcinoma and their association with metastasis and radiotherapy. J Pathol 2006;210:363-73.
40. Ludwig A, Schulte A, Schnack C, et al. Enhanced expression and shedding of the transmembrane chemokine CXCL16 by reactive astrocytes and glioma cells. J Neurochem 2005;93:1293-303.
41. Seidl H, Richtig E, Tilz H, et al. Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Hum Pathol 2007;38:768-80.
42. Wagsater D, Dimberg J. Expression of chemokine receptor CXCR6 in human colorectal adenocarcinomas. Anticancer Res 2004;24:3711-4.
43. Hojo S, Koizumi K, Tsuneyama K, et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 2007;67:4725-31.
44. Derksen P, Liu X, Saridin F, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006;10:437-49.
45. Lin W, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117:1175-83.
46. Aslanian AM, Charo IF. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation 2006;114:583-90.
47. Lin E, Nguyen A, Russell R, Pollard J. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:727-40.